News & Resources

Pharmacyclics Completes $52.4 Million Registered Direct Offering

June 17, 2010

Olshan’s client Pharmacyclics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company, announced that it completed a $52.4 million registered direct offering of its common stock.  Adam Finerman and Jonathan H. Deblinger represented Pharmacyclics in this matter.